|Alphamab Oncology||Alphamab Oncology is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of innovative biotherapeutics for cancer treatment. With multiple in-house proprietary platforms of bispecifics, protein engineering and antibody screening, the company have built a robust pipeline in oncology and immunology with more than 20 phase II-III clinical trials running globally.|
| Huaota |
|Shanghai Huaota Biopharmaceutical Co., Ltd. (aka ‘Huaota’) was established in September 2013. Huaota is a subsidiary of Zhejiang Huahai Pharmaceutical Co., Ltd. Driven by innovation and development.Huaota focuses on the research and development of new biological drugs in the fields of tumor.|
|Wayshine Biopharm, Inc||The company was founded in 2016, now is a clinical stage company. We are forcuse on Discover and develop innovative drugs that cross the blood-brain barrier through to proof-of-concept.Fruitful pipeline for rare disease area-brain cancer and cancers with CNS metastasis. Targeting unique mechanisms of action of hallmarks of brain cancer .|
|ImmuneOnco Biopharma||ImmuneOnco Biopharma, founded in June of 2015 in Zhangjiang High-Tech Park of Shanghai, China, is a clinical-stage biopharmaceutical company dedicated to development and commercialization of innovative cancer immunotherapy.|
The company has established several solid platforms harnessing both innate and adaptive immune cells. Macrophages play a critical role in fighting cancer through phagocytosis followed by presenting of tumor antigen to T cell. However cancer cells are smart and can always find a way to evade the surveillance, such as by over-expressing immune checkpoints including CD47.
ImmuneOnco takes the advantage of the IP-protected SIRPa-domain to develop the mAb-Trap format by which several
bispecific recombinant antibody-receptor proteins have been developed that simultaneously targeting CD47 and other
tumor antigen (TA) such as CD20, Her2, PD-L1, new targets, etc.
|Sinotau Pharmaceutical||Sinotau Pharmaceutical Group was founded in 2005. Through years of R&D efforts the company has developed three clear scopes within the Group, a generic pharma arm, an innovative biological initiative and a nuclear medicine (Radiopharmaceutical) enterprise.|
|AUM Biosciences||The company is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic markers and “undruggable targets”.|
| Sinotau Pharmaceutical||Sinotau Pharmaceutical Group was founded in 2005. Through years of R&D efforts the company has developed three clear scopes within the Group, a generic pharma arm, an innovative biological initiative and a nuclear medicine (Radiopharmaceutical) enterprise.|
| Stemirna Therapeutics||Stemirna Therapeutics was founded by a group of Chinese researchers and scholars in the Zhangjiang Drug Valley of Shanghai in 2016. We are dedicated to developing the best mRNA drug platforms and pipeline.|
| Biocity||Wuxi Biocity was established in December 2017. It is an innovative drug company created by local entrepreneurs who have a deep understanding of the Chinese pharmaceutical market and young returned scientists relying on the world’s leading open drug innovation platform and ecology.|
We are a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated candidates (with no modality limitation) to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
|Biocytogen||The company is a clinical stage biopharmaceutical company that integrates proprietary gene editing technology, transgenic mouse platforms to generate fully human antibodies, comprehensive animal models and high-throughput in vivo antibody discovery.|
|Hinova Pharmaceuticals Inc||Hinova is a global, clinical-stage company focused on the discovery and development for unmet medical needs. With its PROTAC platform and a team of professionals with global pharma R&D experience, Hinova is advancing a pipeline consisting of best-in-class and first-in-class assets for the treatment of cancers and metabolic diseases|
|SciMount Therapeutics||SciMount Therapeutics is a wholly-owned subsidary of XilingLab, focusing on the innovative drug discovery.|
Co-founders：Drs. Jinkun Huang & Dejian Xie
|Mabwell Bioscience||Founded in 2017, Mabwell (Shanghai) Bioscience Co., Ltd is a biopharmaceutical company consisting of 10 subsidiary companies, primary focusing on antibody therapeutics, long-acting protein therapeutics’ R&D and manufacturing. We have over 10 pipeline products in the TA of onco, auto immune, infectious disease and ocular disease. The 1st commercial launch is expected in 2021.|
| AVM Biotech||AVM Biotechnology is a clinical-stage company, founded by Theresa Deisher, Ph.D. The company is developing AVM0703, a proprietary and innovative therapeutic option for cancer and autoimmune diseases. AVM’s passion is to deliver drugs that are effective, safe, work rapidly and are accessible.|